WPW
TCRX icon

Waldron Private Wealth’s TScan Therapeutics TCRX Stock Holding History

Waldron Private Wealth’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$10K – 352
2025
Q4 		$10K Hold
10,000
– – ﹤0.01% 325
2025
Q3 		$18.2K Hold
10,000
– – ﹤0.01% 313
2025
Q2 		$14.5K Hold
10,000
– – ﹤0.01% 298
2025
Q1 		$13.8K Hold
10,000
– – ﹤0.01% 292
2024
Q4 		$30.4K Hold
10,000
– – ﹤0.01% 416
2024
Q3 		$49.8K Hold
10,000
– – ﹤0.01% 439
2024
Q2 		$58.5K Hold
10,000
– – ﹤0.01% 407
2024
Q1 		$79.4K Hold
10,000
– – ﹤0.01% 414
2023
Q4 		$58.3K Hold
10,000
– – ﹤0.01% 404
2023
Q3 		$25.6K Hold
10,000
– – ﹤0.01% 371
2023
Q2 		$25K Hold
10,000
– – ﹤0.01% 370
2023
Q1 		$21K Buy
+10,000
New +$23.7K ﹤0.01% 416

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Waldron Private Wealth's TCRX Position: Q1 2026 in Review

Waldron Private Wealth sold out of TScan Therapeutics (TCRX) in Q1 2026, closing a stake of 10,000 shares — an estimated $10K sold.

Waldron Private Wealth first reported a position in TCRX in Q1 2023 and held it in 12 quarters. The position peaked at $79.4K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Waldron Private Wealth reported no remaining TScan Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Waldron Private Wealth sold 10,000 TScan Therapeutics shares in Q1 2026, an estimated $10K.
  • Waldron Private Wealth first reported a position in TScan Therapeutics in Q1 2023 and held it in 12 quarters.
  • Waldron Private Wealth's TScan Therapeutics position peaked at $79.4K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Waldron Private Wealth's 13F filing for Q1 2026, filed 10 Apr 2026.